NTRB
Nutriband Inc.
Healthcare — Biotechnology
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
None
1 analysts
$7.36
$-0.16 (-2.13%)
Target:
$15.00
(103.8%)
Price History
52-Week Range
Sign in to add NTRB to a watchlist or set price alerts.
Fundamentals
| Market Cap | $37.56M |
| P/E Ratio (TTM) | - |
| Forward P/E | -13.43 |
| EPS (TTM) | $-2.56 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -35.10% |
| ROE | -145.72% |
| Debt/Equity | 3.89 |
| Recommendation | None |
| Analyst Target | $15.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 39.6 |
| Beta | 1.93 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.65 |
| 52-Week Low | $2.90 |
| 50-Day Avg | $3.54 |
| 200-Day Avg | $4.76 |
| Avg Volume | 12.0K |
| Volume | 6.9K |
Performance Analysis
NEUTRALNTRB presents a mixed picture with both positive and negative indicators.
~
Trading at 58% of its 52-week range.
~
RSI at 39.6 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
-
Revenue declined 35.1% year-over-year.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $15.00 implies 103.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report